Researchers identify an early immune trigger for type 1 diabetes, reshaping understanding of the disease’s onset.

INDIANAPOLIS, December 12, 2025: Eli Lilly and Co. announced that its next-generation obesity drug, retatrutide, achieved significant weight loss and reduced knee pain in a late-stage Phase 3 trial, underscoring its potential as a major advance in obesity and osteoarthritis treatment. The TRIUMPH-4 study evaluated retatrutide, a triple-hormone receptor agonist…

WASHINGTON, November 28, 2025: The U.S. Food and Drug Administration (FDA) has expanded a nationwide recall of imported cookware after new testing confirmed that several products may release hazardous levels of lead into food, posing long-term health risks to consumers. The action extends earlier recalls and reflects growing concern over…

WASHINGTON, November 8, 2025: The United States Department of State has issued new instructions to consular offices worldwide expanding the list of medical conditions that may lead to visa denials. Under the updated guidance, chronic illnesses including obesity, diabetes, and cardiovascular disease are now among the factors that visa officers can consider…